The prospect of reducing HIV prevention to just two injections per year represents a fundamental shift in how we approach infectious disease prevention. Unlike daily pill regimens that require perfect adherence, this approach could eliminate the behavioral barriers that have limited PrEP effectiveness in real-world settings. The FDA's approval of lenacapavir for pre-exposure prophylaxis follows clinical trials demonstrating near-perfect protection rates, suggesting a level of efficacy that surpasses existing prevention methods. The drug works by blocking HIV's ability to replicate, providing sustained protection through a novel mechanism that maintains therapeutic levels for six months per injection. This extended duration addresses critical adherence challenges that have hampered traditional daily oral PrEP, particularly among young adults and populations facing stigma or privacy concerns. However, the $28,000 annual price tag in the United States signals a troubling pattern in global health equity. While voluntary licensing agreements with generic manufacturers offer hope for lower-income countries, the pharmaceutical industry's track record suggests significant delays in global rollout. The historical precedent of antiretroviral therapy access reveals how regulatory approval in wealthy nations can precede widespread availability in high-burden regions by years or even decades. This gap is particularly concerning given that sub-Saharan Africa bears the highest HIV incidence rates globally. The breakthrough's true measure lies not in its scientific achievement but in implementation speed across diverse healthcare systems. Without coordinated global action and enforceable access commitments, lenacapavir risks becoming another example of medical innovation that initially widens rather than narrows health disparities.